Xenglu Met 5/500mg Tablets

Xenglu Met 5/500mg Tablets use in Pregnancy

Xenglu Met 5/500mg cannot be ruled out. Lactation: Caution advised or effect undetermined. Contraindications: Renal impairment (serum creatinine level =1,5 mg/dL for males or 1.4 mg/dL for females, or eGFR <45 mL/min/1.73 m2), acute or chronic metabolic acidosis, including diabetic ketoacidosis. Precautions: Monitor renal function before starting treatment and during treatment. Impaired hepatic function.

Indications

Type 2 diabetes mellitus not controlled by metformin alone or by metformin in combination with other antidiabetic drugs or insulin. Dosage Adults 18–84 yrs: 5/500-5/1000 mg twice daily, based on patient’s current metformin dose, increased if required to 12,5/500–12.5/1000 mg twice daily. >85 yrs: Not recommended.

Advice to Patient

Take with meals.

Pharmacokinetics

Xenglu Met 5/500mg: Metabolism: Hepatico Half-life elimination: 12.4 hrs. Time to peak: 1.5 hrs. Excretion: Urine (54.4%). Faeces (41.2%). METFORMIN: Onset of action: Within days, max effects up to 2 wks. Metabolismo Not metabolized by the liver. Bioavailability: Absolute: Fasting: 50%-60%. Half-life elimination: Plasma: 4-9 hrs. Blood: Approx. 17,6 hrs. Time to peak, serum: Immediate release: 2-3 hrs. Extended release: 7 hrs. (Range: 4-8 hrs). Excretion: Urine.

Interactions

Ranolazine, selegiline, tranylcypromine, topiramate and other carbonic anhydrase inhibitors, thiazides and other diuretics.

Adverse effects

Lactic acidosis, genital mycotic infections, UTIS, vitamin B12 deficiency, increased LDL-C.